insights_auto
为什么 HROW 下跌了 3.80%?
深入探索chevron_right
HROW:NASDAQ
Harrow Inc
US$29.36
arrow_downward
-3.80%(-1.16) 1 天
US$29.61
arrow_upward
+0.85% (+0.25)bedtime盘后交易
休市： 10月9日, GMT-4 16:00:01 · USD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 HROW 生成关键数据洞见…
开盘价
US$30.73
最高价
US$30.90
最低价
US$27.00
市值
11.01亿
平均成交量
55.02万
成交量
135.24万
52 周最高价
US$54.85
52 周最低价
US$27.00
每股收益
-US$1.00
Beta 版
0.19
流通股数
3748.80万
员工人数
373
开盘价
US$30.73
最高价
US$30.90
最低价
US$27.00
市值
11.01亿
平均成交量
55.02万
成交量
135.24万
52 周最高价
US$54.85
52 周最低价
US$27.00
每股收益
-US$1.00
Beta 版
0.19
流通股数
3748.80万
员工人数
373
新闻报道
来自网络来源和新闻合作伙伴
Investing.com
·
1天前
Harrow stock hits 52-week low at 28.51 USD
Simply Wall Street
·
1天前
Clinical Data Showcase Could Be A Game Changer For Harrow (HROW)
资料
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
Harrow Inc简介